FIELD: pharmacy.
SUBSTANCE: invention refers to determination of the level of marker peptides in the sample obtained from the body fluid of the subject, admitted to the emergency department with nonspecific complaints. The invention discloses a method for estimation of the adverse events probability for such patient, prediction of his/her viability or for taking of concrete decisions concerning his/her treatment, which includes determination of the level of marker peptide selected from the group consisting of proANP, proBNP, proAVP, proADM, proET-1, the PCT, the PRX-4 or fragments thereof comprising at least 12 amino acids in length.
EFFECT: marker peptides, or fragments thereof are independent prognostic factors for serious conditions, including death and hospitalization for patients brought to the emergency medicine department with nonspecific complaints.
17 cl, 45 dwg, 16 tbl
